American CryoStem Issues Shareholder Update Letter

EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK:CRYO) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone.

Dear American CryoStem family, partners and shareholders,

I write to you today with gratitude, pride and excitement. Gratitude and pride for the dedication and support of our employees, partners and shareholders in our accomplishments to date, and great excitement for the value I see for us in the path ahead.

With our main 4 core patents (collect-process-store-return to point of care) granted we are now entering the exciting commercialization phase. Timing has coincided with two specific areas of unmet medical needs; the global COVID-19 pandemic and Traumatic Brain Injury (TBI), which are particularly a point of focus for the U.S. military, the Veterans Administration and the National Football League (NFL).

Our pipeline of opportunities is at its highest in Company history. As cellular therapy becomes front and center as a potential treatment modality for COVID-19, there is robust interest in our proprietary autologous adult stem cell platform as the potential for reinfection grows and the virus mutates and spreads.

Our Company is well-positioned in Regenerative and Personalized medicine. Our patented adult stem cell ‘end-to-end' platform for thecollection, processing, transportation, storage and return to point-of-care is well suited for successive personalized treatments relating to COVID-19 and the long-term health effects associated with the virusidentified as "Post Viral Syndrome",

Our business/economic model is multi-pronged and encompasses a domestic network of over 125 physicians in 38 states and a growing global footprint of licensed facilities operating on our cellular platform..

In the U.S., we are receiving institutional interest inour cellular therapy platform in response to the COVID-19 pandemic and regenerative therapies are being investigated for limiting the damage caused by the virus.

Another area of focus in the U.S., and potentially internationally, is our use of stem cells in addressing the unmet need for Post-Concussion Syndrome (PCS). There are over 10 million concussions worldwide annually,occurring every 15 seconds. In the U.S., approximately 30% of overseas deployed military sustain head trauma. Head trama is a major systemic medical problem confronting the military for which therapeutic solutions are being sought. The NFL Concussion Settlement Program Fund committed $2 billion over 65 years to seek treatment modalities to ameliorate collateral effects of concussions and Traumatic Brain Injury (TBI).

We have developed an autologous therapy treatment focused on alleviating and/or ameliorating neurological, cognitive and functional effects of Post Concussion Syndrome (PCS) and complications related toTBI (Traumatic Brain Injury). Currently, there are no FDA approved drugs or cellular therapies available designed to treat the inflammatory responses or repair the physical damage to the brain. Our focus is to provide the opportunity to mitigate life altering damage caused by such head trauma and related conditions to improve patient health, quality of life and well-being.

During Q4 -2019 we filed a "Foundational" IND (Investigational New Drug) application with the FDA to initiate a Phase I Clinical Trial (safety study, FDA File No. 19089) for Post Concussion Syndrome (PCS).

We believe that an FDA, IND study approval will recognize that our autologous cells, "Collect - Process - CryoBank - Return to Point of Care" Foundational Platform and Centralized Laboratory model is both safe, efficacious and cost effective for the production and administration of our proprietary ATCELL™ product via IV infusion.

Internationally, we are excited about opportunities with our Thailand partner, CryoViva, a Bangkok, Thailand based umbilical cord, processing and storage company. While the COVID-19 pandemic has pushed back Cryoviva's marketing campaign in Thailand and South East Asia, it is expected to begin over the next few months.We expect to see an increase in the sale of consumables and licensing fees upon launch.

The Company is optimistic about its future in the rapidly growing Regenerative and Personalized Medicine industry. We plan on ramping our revenue over the next 12 months as we continue to focus on expanding our international licensing platform and augmenting our physician network and customer base domestically. We are indeed standing at the forefront of a new era, during which unprecedented medical breakthroughs will continue on a near routine basis thanks to the increasing understanding of the power and capabilities of human adult stem cells.

In closing, I would like to use this opportunity to express my sincere appreciation to all of our shareholders for your commitment to American CryoStem's mission and for your continued trust and confidence in our industry and leadership.


John S. Arnone, CEO
American CryoStem Corporation

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), a pioneer in the fields of Regenerative and Personalized Medicine, is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation laboratory facility in Monmouth Junction, New Jersey.

For additional information, please visit:

Forward-looking Statements:

This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.

Corporate Contact:

P 732-747-1007



SOURCE: American CryoStem Corporation


View source version on


Back to news